Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around
Principal Investigator
by David Oh (ucsf)
Headshot of David Oh
David Oh

Description

Summary

This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.

Official Title

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Keywords

Advanced/Metastatic Clear Cell Renal Cell Carcinoma, CAR T, Cell Therapy, Allogeneic Cell Therapy, Cellular Immuno-therapy, AlloCAR T, ALLO-316, ALLO-647, CCRCC, Clear Cell Renal Cell Carcinoma, Carcinoma, Renal Cell Carcinoma, Cyclophosphamide, Fludarabine, ALLO-647, ALLO-316

Eligibility

Locations

  • UCLA Medical Center accepting new patients
    Los Angeles California 90095 United States
  • UCSF Medical Center accepting new patients
    San Francisco California 94143 United States
  • City of Hope terminated
    Duarte California 91010 United States

Lead Scientist at University of California Health

  • David Oh (ucsf)
    I am a physician-scientist focused on developing novel immunotherapies with enhanced activity and reduced toxicity, for patients with solid cancers. Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR).

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allogene Therapeutics
ID
NCT04696731
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 120 study participants
Last Updated